Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

AIM : Interleukin-33 (IL-33) has recently been implicated in tumor immunity. The aim of this study was to explore the clinical role of serum IL-33 in patients with non-small-cell lung cancer (NSCLC).METHODS:Sera collected from 126 healthy volunteers (HV), 148 patients with benign lung diseases (BLD) and 103 NSCLC cases were subjected to IL-33 ELISA and relationships between serum IL-33 and clinical characteristics were evaluated.RESULTS:Circulating IL-33 levels were higher in the NSCLC group in comparison with the HV and BLD groups (p<0.001). Using a cut-off level 63 pg/ml (95% specificity in the HV group), IL-33 showed a good diagnostic performance for NSCLC. Multivariate survival analysis indicated that serum IL-33 was an independent prognostic factor in the entire NSCLC group [hazards ratio (HR) = 0.69 for low versus high IL-33 levels, 95% confidence interval (CI) 0.54-0.87; p<0.001] and in 71 selected patients with locally advanced or metastatic disease receiving chemoradiotherapy or chemotherapy (HR 0.80, 95% CI 0.49-0.95; p=0.015).CONCLUSIONS:IL-33 is a promising potential diagnostic and prognostic marker in NSCLC, independent of the therapeutic interventionKey words: non-small cell lung cancer, interleukin-33, diagnostic marker, prognostic marker.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Petrovic, I. Cekerevac, D. Petrovic, R. Vucic, I. Simic (Kragujevac, Republic Of Serbia). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Eur Respir J 2014; 44: Suppl. 58, 516

Member's Comments

No comment yet.

Related content which might interest you: The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 PIWI proteins as prognostic markers in non small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Serum osteopontin as a prognostic marker in patients with lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 MUC1 gene polymorphism and serum KL-6 in lung adenocarcinoma Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Association between leptin and risk of lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Lactat-dehydrogenase, C-reactive protein and white blood cell count are prognostic factors in advanced small cell lung cancer (SCLC) Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014